3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase NA
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
139
Carcinoma, Non-Small-Cell Lung
109
Prostatic Neoplasms
51
Lung Neoplasms
31
Neoplasm Metastasis
21
Stomach Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Nasopharyngeal Carcinoma
16
Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Esophageal Neoplasms
11
Head and Neck Neoplasms
8
Esophageal Squamous Cell Carcinoma
8
Urinary Bladder Neoplasms
7
HER2-positive Breast Cancer
7
Ovarian Neoplasms
6
Carcinoma
6
Adenocarcinoma
6
Inflammatory Breast Neoplasms
5
Fallopian Tube Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Squamous Cell
5
Adenocarcinoma of Lung
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Carcinoma, Transitional Cell
4
Adenocarcinoma Of Esophagus
4
Primary Breast Cancer
3
Carcinoma, Ovarian Epithelial
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Interventions
Gemcitabine
11
Cisplatin
11
Radiotherapy, Intensity-Modulated
6
tislelizumab
2
nimotuzumab
2
camrelizumab
2
Fluorouracil
2
Carboplatin
2
spartalizumab
1
sintilimab
1
sargramostim
1
pembrolizumab
1
fosaprepitant
1
etoposide phosphate
1
Tropisetron
1
Radiotherapy
1
Induction Chemotherapy
1
Ifosfamide
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Chemotherapy, Adjuvant
1
Chemoradiotherapy
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Nasopharyngeal Neoplasms
×
Docetaxel
×
Clear all
NCT02611960
2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3
Completed
233 enrolled
21 charts